

## Northwestern University Institutional Biosafety Committee

### Meeting Minutes

Date: 10/15/2025 11:00 AM

Called to Order:

Adjourned:

Location: 345 E Superior St, Suite 1522, Chicago, IL 60611

Northwestern University conducts some or all of its IBC meetings via teleconference (either Zoom or Microsoft Teams, as Northwestern policy requires). A public meeting notice was posted; no comments or attendance requests were received. Attendees of a Northwestern IBC meeting are reminded of confidentiality and conflict of interest expectations. A public meeting notice was posted on the Research Safety website and no public comment was received.

#### IBC Members

Name	Committee Role	Attendance
Mary Hummel	Chair	-
Greg Smith	Chair	-
Gregory Beitel	Member	-
Jennifer Brace	Member	Confirmed
Jacob Class	Member	-
Alexis Demonbreun	Member	-
Adriana Ferreira	Member	-
Robert Foreman	Member	-
Susan Fox	Member	-
Lucy Godley	Member	-
Erica Hartmann	Member	-
Sydni Hill	Member	-
Robert Holmgren	Member	-
Changhwa Hwang	Member	-
Sarah Kopp	Member	Confirmed
Maciej Lesniak	Member	-
Stephen Levin	Member	-
Liming Li	Member	-
Emma Liechty	Member	-
Michael McRaven	Member	-
Jeremy T Ritzert	Member	-
Irina Shepotinovskaya	Member	-
Suchitra Swaminathan	Member	-
Clyde Yancy	Member	-
Nicolette Zielinski-Mozny	Member	-
Robert Birkett	Alternate	-
Jane Cullen	Alternate	-
Mandy Kozlowski	Alternate	-
Alicia McLuckie	Alternate	-

<b>Name</b>	<b>Committee Role</b>	<b>Attendance</b>
Marina Zelivyanskaya	Alternate	-
James Zewe	Alternate	-
Michael Hantak	Administrator	-
Iwona Spath	Administrator	-

#### **Registrations for Full-Committee Review**

<b>Research Group</b>	<b>Principal Investigator</b>	<b>Submission Type</b>
Akhtar (Lisa) Lab	Lisa Akhtar	Initial Protocol
Amendment for BIO20230124	Bria Coates	Amendment
Amendment for BIO20220034	Lillian Eichner	Amendment
Amendment for BIO20220017	Nayereh Ghoreishi	Amendment
Grote Lab	Alexandra Grote	Initial Protocol
Heimberger Lab	Amy Heimberger	Initial Protocol
Kamat Lab	Neha Kamat	Initial Protocol
Kelleher Lab	Neil Kelleher	Initial Protocol
Kwon Lab	Jennie Kwon	Initial Protocol
Oudega Lab	Martin Oudega	Initial Protocol
Amendment/CR for BIO20230001	Derek Walsh	Amendment/CR

#### **Approval of Previous Meeting Minutes**

Previous Meeting Date: 9/17/25

Determination:

Comments: A Committee Member made a motion to approve the meeting minutes. The Committee unanimously supported the motion.

## Meeting Minutes

### Review of Akhtar (Lisa) Lab

#### Initial Protocol

**Principal Investigator:** Lisa Akhtar

**Submission ID:** BIO20250035

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications/defer this submission.

The Committee unanimously supported the motion.

## **Review of Amendment for BIO20230124**

### **Amendment**

**Principal Investigator:** Bria Coates

**Submission ID:** BIO20230124-AM0001

#### **Applicable NIH Guidelines:**

- Section III-D-7
- Section III-E-3-a
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-4-c-(2)
- Section III-E-2-b-(5)
- Section III-D-2
- Section III-D
- Section III-F-8

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications/defer this submission.

The Committee unanimously supported the motion.

## **Review of Amendment for BIO20220034**

### **Amendment**

**Principal Investigator:** Lillian Eichner

**Submission ID:** BIO20220034-AM0001

**Applicable NIH Guidelines:**

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Highest Applicable Containment Level for Proposed Look:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications/defer this submission.

The Committee unanimously supported the motion.

## **Review of Amendment for BIO20220017**

### **Amendment**

**Principal Investigator:** Nayereh Ghoreishi

**Submission ID:** BIO20220017-AM0017

**Applicable NIH Guidelines:**

- Section III-D-4-b
- Section III-D-4
- Section III-D-4-c-(1)
- Section III-F
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-F-8-C-VIII
- Section III-F-8

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approve

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications/defer this submission.

The Committee unanimously supported the motion.

## **Review of Grote Lab**

Initial Protocol

**Principal Investigator:** Alexandra Grote

**Submission ID:** BIO20250102

**Applicable NIH Guidelines:**

- Section III-F
- Section III-F-1

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications /defer this submission.

The Committee unanimously supported the motion.

## **Review of Heimberger Lab**

Initial Protocol

**Principal Investigator:** Amy Heimberger

**Submission ID:** BIO20250033

### **Applicable NIH Guidelines:**

- Section III-D-1-a
- Section III-F-2
- Section III-E-3
- Section III-E-3-a
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-D-3-a
- Section III-F-8-C-VIII
- Section III-F-8

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications / defer this submission.

The Committee unanimously supported the motion.



## **Review of Kamat Lab**

### **Initial Protocol**

**Principal Investigator:** Neha Kamat

**Submission ID:** BIO20240175

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8-C-VIII
- Section III-F-8

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications / defer this submission.

The Committee unanimously supported the motion.

## **Review of Kelleher Lab**

### **Initial Protocol**

**Principal Investigator:** Neil Kelleher

**Submission ID:** BIO20240125

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-F
- Section III-F-1
- Section III-F-8

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications / defer this submission.

The Committee unanimously supported the motion.

## **Review of Kwon Lab**

### **Initial Protocol**

**Principal Investigator:** Jennie Kwon

**Submission ID:** BIO20250095

**Applicable NIH Guidelines:**

- Section III-F
- Section III-F-1

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications / defer this submission.

The Committee unanimously supported the motion.

## **Review of Oudega Lab**

Initial Protocol

**Principal Investigator:** Martin Oudega

**Submission ID:** BIO20240085

**Applicable NIH Guidelines:**

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications / defer this submission..

The Committee unanimously supported the motion.

## **Review of Amendment/CR for BIO20230001**

Amendment/CR

**Principal Investigator:** Derek Walsh

**Submission ID:** BIO20230001-AMCR0001

### **Applicable NIH Guidelines:**

- Section III-D-1-a
- Section III-C
- Section III-F-3
- Section III-F-8-C-I
- Section III-F
- Section III-E
- Section III-D-2-a
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-E-1
- Section III-D-3-a
- Section III-F-6

**Highest Applicable Containment Level for Proposed Look:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications / defer this submission.

The Committee unanimously supported the motion.

## **Administratively-Approved Exempt Registrations and Amendments**

### **Continuing Review for BIO20240058**

#### **Continuing Review**

**Principal Investigator:** Apkar Apkarian

**Submission ID:** BIO20240058-CR0001

**Applicable NIH Guidelines:**

- Section III-D-1-a
- Section III-E-3
- Section III-D-4-b
- Section III-D-4-a
- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8-C-VII
- Section III-D
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 8/4/2025

### **Continuing Review for BIO20220061**

#### **Continuing Review**

**Principal Investigator:** Vadim Backman

**Submission ID:** BIO20220061-CR0001

**Applicable NIH Guidelines:**

- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 10/6/2025

## **Continuing Review for BIO20240082**

### **Continuing Review**

**Principal Investigator:** Xiaomin Bao

**Submission ID:** BIO20240082-CR0001

**Applicable NIH Guidelines:**

- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2+

**Approval Date:** 10/13/2025

## **Continuing Review for BIO20240040**

### **Continuing Review**

**Principal Investigator:** Edith Chen

**Submission ID:** BIO20240040-CR0001

**Applicable NIH Guidelines:**

- Section III-F
- Section III-F-1

**Containment Level:** BSL-2

**Approval Date:** 9/19/2025

## **Amendment for BIO20240107**

### **Amendment**

**Principal Investigator:** Insup Choi

**Submission ID:** BIO20240107-AM0002

**Applicable NIH Guidelines:**

- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-D-4-c-(1)
- Section III-F
- Section III-F-1
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-4-c
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 10/1/2025

## **Continuing Review for BIO20230099**

### **Continuing Review**

**Principal Investigator:** Carla Cuda

**Submission ID:** BIO20230099-CR0002

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-E-3-a
- Section III-F
- Section III-E
- Section III-F-8-C-VII
- Section III-F-8-C-VIII

**Containment Level:** BSL-2

**Approval Date:** 10/6/2025

## **Amendment for BIO20230087**

### **Amendment**

**Principal Investigator:** Shawn Davidson

**Submission ID:** BIO20230087-AM0002

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 9/10/2025

## **Continuing Review for BIO20240123**

### **Continuing Review**

**Principal Investigator:** Michael DeCuypere

**Submission ID:** BIO20240123-CR0001

**Applicable NIH Guidelines:**

**Containment Level:** BSL-2

**Approval Date:** 9/19/2025



## **Amendment/CR for BIO20240098**

### **Amendment/CR**

**Principal Investigator:** Alexis Demonbreun

**Submission ID:** BIO20240098-AMCR0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-F
- Section III-E
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 9/24/2025

## **Amendment for BIO20220031**

### **Amendment**

**Principal Investigator:** Francesca Duncan

**Submission ID:** BIO20220031-AM0003

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-3-d
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 10/6/2025

## **Amendment for BIO20220096**

### **Amendment**

**Principal Investigator:** Amani Fawzi

**Submission ID:** BIO20220096-AM0001

**Applicable NIH Guidelines:**

- Section III-D-4
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 10/13/2025

## **Continuing Review for BIO20220117**

### **Continuing Review**

**Principal Investigator:** Vladimir Gelfand

**Submission ID:** BIO20220117-CR0002

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-D-4
- Section III-F
- Section III-E
- Section III-D
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 10/6/2025

## **Continuing Review for BIO20240137**

### **Continuing Review**

**Principal Investigator:** Andrew Gordon

**Submission ID:** BIO20240137-CR0001

**Applicable NIH Guidelines:**

**Containment Level:** BSL-1

**Approval Date:** 10/3/2025

## **Continuing Review for BIO20240088**

### **Continuing Review**

**Principal Investigator:** Curt Horvath

**Submission ID:** BIO20240088-CR0001

**Applicable NIH Guidelines:**

- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 9/19/2025

## **Continuing Review for BIO20220145**

### **Continuing Review**

**Principal Investigator:** Mark Johnson

**Submission ID:** BIO20220145-CR0002

**Applicable NIH Guidelines:**

- Section III-F
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 9/19/2025

## **Continuing Review for BIO20240036**

### **Continuing Review**

**Principal Investigator:** J. Julie Kim

**Submission ID:** BIO20240036-CR0001

**Applicable NIH Guidelines:**

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2+

**Approval Date:** 9/24/2025

## **Continuing Review for BIO20240087**

### **Continuing Review**

**Principal Investigator:** Keara Lane

**Submission ID:** BIO20240087-CR0001

**Applicable NIH Guidelines:**

- Section III-D-1-a
- Section III-F
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-D-3-a
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 9/25/2025

## **Continuing Review for BIO20240042**

### **Continuing Review**

**Principal Investigator:** Caroline Le Poole

**Submission ID:** BIO20240042-CR0001

**Applicable NIH Guidelines:**

- Section III-F
- Section III-F-1
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 9/11/2025

## **Amendment for BIO20220133**

### **Amendment**

**Principal Investigator:** Hao Li

**Submission ID:** BIO20220133-AM0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 9/25/2025

## **Continuing Review for BIO20230114**

### **Continuing Review**

**Principal Investigator:** Elena Martinelli

**Submission ID:** BIO20230114-CR0001

**Applicable NIH Guidelines:**

- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-D-3
- Section III-D-3-a
- Section III-F-8

**Containment Level:** BSL-2+

**Approval Date:** 9/11/2025

## **Continuing Review for BIO20220107**

### **Continuing Review**

**Principal Investigator:** Daniela Menichella

**Submission ID:** BIO20220107-CR0002

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-E-3-a
- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 9/22/2025

## **Continuing Review for BIO20220138**

### **Continuing Review**

**Principal Investigator:** Richard Miller

**Submission ID:** BIO20220138-CR0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-E-3-a
- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 4/3/2025

## **Amendment for BIO20230077**

### **Amendment**

**Principal Investigator:** Chad Mirkin

**Submission ID:** BIO20230077-AM0001

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-E-3
- Section III-F-8-C-I
- Section III-D-4
- Section III-F
- Section III-F-8-C-VI
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3

**Containment Level:** BSL-2

**Approval Date:** 10/2/2025

## **Continuing Review for BIO20240156**

### **Continuing Review**

**Principal Investigator:** Vijay Mittal

**Submission ID:** BIO20240156-CR0001

**Applicable NIH Guidelines:**

**Containment Level:** BSL-2

**Approval Date:** 10/14/2025

## **Continuing Review for BIO20240076**

### **Continuing Review**

**Principal Investigator:** Alfonso Mondragon

**Submission ID:** BIO20240076-CR0001

**Applicable NIH Guidelines:**

- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-F-4
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 9/19/2025

## **Continuing Review for BIO20230051**

### **Continuing Review**

**Principal Investigator:** Jeremy O'Sullivan

**Submission ID:** BIO20230051-CR0002

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-E-3
- Section III-F-3
- Section III-D-4
- Section III-E
- Section III-D-1
- Section III-F-8

**Containment Level:** BSL-2+

**Approval Date:** 9/11/2025

## **Continuing Review for BIO20240116**

### **Continuing Review**

**Principal Investigator:** Jones Parker

**Submission ID:** BIO20240116-CR0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4-b
- Section III-E-3-a
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-4-c

**Containment Level:** BSL-2

**Approval Date:** 9/3/2025

## **Amendment for BIO20240134**

### **Amendment**

**Principal Investigator:** Lucas Pinto

**Submission ID:** BIO20240134-AM0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4-a
- Section III-F
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-1

**Approval Date:** 10/3/2025

## **Continuing Review for BIO20240134**

### **Continuing Review**

**Principal Investigator:** Lucas Pinto

**Submission ID:** BIO20240134-CR0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4-a
- Section III-F
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-1

**Approval Date:** 9/23/2025

## **Amendment/CR for BIO20220002**

### **Amendment/CR**

**Principal Investigator:** Leonidas Platanias

**Submission ID:** BIO20220002-AMCR0001

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-E-3
- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 9/15/2025



## **Continuing Review for BIO20220026**

### **Continuing Review**

**Principal Investigator:** Wenan Qiang

**Submission ID:** BIO20220026-CR0001

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-F-8-C-I
- Section III-F
- Section III-F-8-C-II

**Containment Level:** BSL-2

**Approval Date:** 9/19/2025

## **Continuing Review for BIO20240019**

### **Continuing Review**

**Principal Investigator:** Jeffrey Savas

**Submission ID:** BIO20240019-CR0002

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 10/3/2025

## **Amendment for BIO20240145**

### **Amendment**

**Principal Investigator:** Robert Vassar

**Submission ID:** BIO20240145-AM0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-E
- Section III-F-8-C-VII
- Section III-D-3

**Containment Level:** BSL-2

**Approval Date:** 9/19/2025

## **Continuing Review for BIO20230115**

### **Continuing Review**

**Principal Investigator:** Bowen Wang

**Submission ID:** BIO20230115-CR0002

#### **Applicable NIH Guidelines:**

- Section III-D-1-a
- Section III-E-3
- Section III-D-4-b
- Section III-F-8-C-I
- Section III-D-4-a
- Section III-D-4
- Section III-D-4-c-(1)
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-4-c
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 9/29/2025

## **Amendment for BIO20250003**

### **Amendment**

**Principal Investigator:** Lu Wang

**Submission ID:** BIO20250003-AM0001

#### **Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2+

**Approval Date:** 9/25/2025

## **Amendment/CR for BIO20220113**

### **Amendment/CR**

**Principal Investigator:** Adam Williams

**Submission ID:** BIO20220113-AMCR0001

#### **Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-7
- Section III-D-4-b
- Section III-D-4-a
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 10/6/2025

## **Continuing Review for BIO20240108**

### **Continuing Review**

**Principal Investigator:** Waihay Wong

**Submission ID:** BIO20240108-CR0001

#### **Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2+

**Approval Date:** 9/30/2025

## **Continuing Review for BIO20240159**

### **Continuing Review**

**Principal Investigator:** M.-N. Frances Yap

**Submission ID:** BIO20240159-CR0001

**Applicable NIH Guidelines:**

- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 9/19/2025

## **Amendment for BIO20220127**

### **Amendment**

**Principal Investigator:** Peng Zhang

**Submission ID:** BIO20220127-AM0003

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 9/19/2025

## **Other Agenda Items**

**Description:** As requested in the July IBC Meeting, the Zhao (Youyang) Lab has provided the committee with their toxin use log at the beginning of October.

**Related Projects:** BIO20240038

**Notes:**